Validation and Characterization of FGFR2 Rearrangements in Cholangiocarcinoma with Comprehensive Genomic Profiling
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Validation and Characterization of FGFR2 Rearrangements in Cholangiocarcinoma with Comprehensive Genomic Profiling
Authors
Keywords
-
Journal
JOURNAL OF MOLECULAR DIAGNOSTICS
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2022-02-15
DOI
10.1016/j.jmoldx.2021.12.012
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Final results from ClarIDHy, a global, phase III, randomized, double-blind study of ivosidenib (IVO) versus placebo (PBO) in patients (pts) with previously treated cholangiocarcinoma (CCA) and an isocitrate dehydrogenase 1 (IDH1) mutation.
- (2021) Andrew X. Zhu et al. JOURNAL OF CLINICAL ONCOLOGY
- Pemigatinib for previously treated locally advanced/metastatic cholangiocarcinoma (CCA): Update of FIGHT-202.
- (2021) Ghassan K. Abou-Alfa et al. JOURNAL OF CLINICAL ONCOLOGY
- Global incidence of and trends in intrahepatic and extrahepatic cholangiocarcinoma from 1993 to 2012
- (2020) Andrea A. Florio et al. CANCER
- A phase III study of futibatinib (TAS-120) versus gemcitabine-cisplatin (gem-cis) chemotherapy as first-line (1L) treatment for patients (pts) with advanced (adv) cholangiocarcinoma (CCA) harboring fibroblast growth factor receptor 2 (FGFR2) gene rearrangements (FOENIX-CCA3).
- (2020) Mitesh J. Borad et al. JOURNAL OF CLINICAL ONCOLOGY
- Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials
- (2020) David S Hong et al. LANCET ONCOLOGY
- Efficacy of FGFR Inhibitors and Combination Therapies for Acquired Resistance in FGFR2-Fusion Cholangiocarcinoma
- (2020) Melanie A. Krook et al. MOLECULAR CANCER THERAPEUTICS
- Genomic basis for RNA alterations in cancer
- (2020) Claudia Calabrese et al. NATURE
- PROOF 302: A randomized, double-blind, placebo-controlled, phase III trial of infigratinib as adjuvant therapy in patients with invasive urothelial carcinoma harboring susceptible FGFR3 alterations.
- (2020) Siamak Daneshmand et al. JOURNAL OF CLINICAL ONCOLOGY
- Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma
- (2020) Robert Montal et al. JOURNAL OF HEPATOLOGY
- Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study
- (2020) Ghassan K Abou-Alfa et al. LANCET ONCOLOGY
- Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study
- (2020) Ghassan K Abou-Alfa et al. LANCET ONCOLOGY
- Epidemiology of Cholangiocarcinoma; United States Incidence and Mortality Trends
- (2020) Mohamed M. Gad et al. Clinics and Research in Hepatology and Gastroenterology
- FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with FGFR2 rearrangements
- (2020) Tanios S Bekaii-Saab et al. Future Oncology
- Brigatinib Versus Crizotinib in Advanced ALK Inhibitor–Naive ALK-Positive Non–Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial
- (2020) D. Ross Camidge et al. JOURNAL OF CLINICAL ONCOLOGY
- Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study
- (2020) Aurélien Marabelle et al. LANCET ONCOLOGY
- Molecular Profiling in Daily Clinical Practice: Practicalities in Advanced Cholangiocarcinoma and Other Biliary Tract Cancers
- (2020) Angela Lamarca et al. Journal of Clinical Medicine
- Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer
- (2020) Thierry André et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinicogenomic Analysis of FGFR2-Rearranged Cholangiocarcinoma Identifies Correlates of Response and Mechanisms of Resistance to Pemigatinib
- (2020) Ian M. Silverman et al. Cancer Discovery
- AB065. P-36. Debio 1347 in patients with cholangiocarcinoma harboring an FGFR gene alteration: preliminary results
- (2019) Matthew C. H. Ng et al. HEPATOBILIARY SURGERY AND NUTRITION
- AB051. P-19. A phase II study of infigratinib (BGJ398) in previously-treated advanced cholangiocarcinoma containing FGFR2 fusions
- (2019) Milind Javle et al. HEPATOBILIARY SURGERY AND NUTRITION
- Cholangiocarcinoma: Epidemiology and risk factors
- (2019) Shahid A. Khan et al. LIVER INTERNATIONAL
- A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring FGFR Gene Alterations
- (2019) Martin H. Voss et al. CLINICAL CANCER RESEARCH
- Distinct histomorphological features are associated with IDH1 mutation in intrahepatic Cholangiocarcinoma
- (2019) Tao Wang et al. HUMAN PATHOLOGY
- ABC-06 | A randomised phase III, multi-centre, open-label study of active symptom control (ASC) alone or ASC with oxaliplatin / 5-FU chemotherapy (ASC+mFOLFOX) for patients (pts) with locally advanced / metastatic biliary tract cancers (ABC) previously-treated with cisplatin/gemcitabine (CisGem) chemotherapy.
- (2019) Angela Lamarca et al. JOURNAL OF CLINICAL ONCOLOGY
- Derazantinib (DZB) provides antitumor efficacy regardless of line of therapy in patients (pts) with FGFR2-fusion positive advanced intrahepatic cholangiocarcinoma (iCCA).
- (2019) Michele Droz Dit Busset et al. JOURNAL OF CLINICAL ONCOLOGY
- TAS-120 overcomes resistance to ATP-competitive FGFR inhibitors in patients with FGFR2 fusion-positive intrahepatic cholangiocarcinoma
- (2019) Lipika Goyal et al. Cancer Discovery
- Second‐line chemotherapy in advanced biliary cancers: A retrospective, multicenter analysis of outcomes
- (2019) Maeve A. Lowery et al. CANCER
- 721PEfficacy of derazantinib (DZB) in patients (pts) with intrahepatic cholangiocarcinoma (iCCA) expressing FGFR2-fusion or FGFR2 mutations/amplifications
- (2019) M Droz Dit Busset et al. ANNALS OF ONCOLOGY
- Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials
- (2019) Alexander Drilon et al. LANCET ONCOLOGY
- Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials
- (2019) Robert C Doebele et al. LANCET ONCOLOGY
- Comprehensive molecular profiling of intra- and extrahepatic cholangiocarcinomas: potential targets for intervention
- (2018) Maeve A Lowery et al. CLINICAL CANCER RESEARCH
- Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma
- (2018) Milind Javle et al. JOURNAL OF CLINICAL ONCOLOGY
- Trends in Incidence and Factors Affecting Survival of Patients With Cholangiocarcinoma in the United States
- (2018) Shiva Kumar R. Mukkamalla et al. Journal of the National Comprehensive Cancer Network
- Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma
- (2018) Vincenzo Mazzaferro et al. BRITISH JOURNAL OF CANCER
- Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
- (2017) Ahmet Zehir et al. NATURE MEDICINE
- Cholangiocarcinoma — evolving concepts and therapeutic strategies
- (2017) Sumera Rizvi et al. Nature Reviews Clinical Oncology
- Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma
- (2017) Apinya Jusakul et al. Cancer Discovery
- Biliary cancer: Utility of next-generation sequencing for clinical management
- (2016) Milind Javle et al. CANCER
- Comprehensive genomic profiling of extrahepatic cholangiocarcinoma reveals a long tail of therapeutic targets
- (2015) Hwajeong Lee et al. JOURNAL OF CLINICAL PATHOLOGY
- Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma
- (2014) Rondell P. Graham et al. HUMAN PATHOLOGY
- Cholangiocarcinoma
- (2014) Nataliya Razumilava et al. LANCET
- Anchored multiplex PCR for targeted next-generation sequencing
- (2014) Zongli Zheng et al. NATURE MEDICINE
- New Routes to Targeted Therapy of Intrahepatic Cholangiocarcinomas Revealed by Next-Generation Sequencing
- (2014) J. S. Ross et al. ONCOLOGIST
- Mutation Profiling in Cholangiocarcinoma: Prognostic and Therapeutic Implications
- (2014) Chaitanya R. Churi et al. PLoS One
- Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma
- (2013) Yasuhito Arai et al. HEPATOLOGY
- Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing
- (2013) Garrett M Frampton et al. NATURE BIOTECHNOLOGY
- Frequent Mutation of Isocitrate Dehydrogenase (IDH)1 and IDH2 in Cholangiocarcinoma Identified Through Broad-Based Tumor Genotyping
- (2011) D. R. Borger et al. ONCOLOGIST
- Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
- (2010) Juan Valle et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Prognosis and Survival Outcome of Intrahepatic Cholangiocarcinoma Following Surgical Resection: Association of Lymph Node Metastasis and Lymph Node Dissection with Survival
- (2009) Sae-Byeol Choi et al. ANNALS OF SURGICAL ONCOLOGY
- Aberrant Receptor Internalization and Enhanced FRS2-dependent Signaling Contribute to the Transforming Activity of the Fibroblast Growth Factor Receptor 2 IIIb C3 Isoform
- (2008) Jiyoung Y. Cha et al. JOURNAL OF BIOLOGICAL CHEMISTRY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started